TransAlgae

Company Overview

Snapshot

Founded in May 2008 by Maor Sasson, Doron Eisenstadt, and Ofra Chen, TransAlgae operates with 11–50 employees. The company has raised $29.52M across 6 funding rounds from 2 investors. In April 2021, TransAlgae secured an additional $2.5M for its algae-based oral vaccine solution, highlighting continued investor confidence in its innovative drug delivery platform.

Business overview

TransAlgae develops an algae-based platform for the oral delivery of drugs, including vaccines, immune modulators, and insecticides. This technology is applied across human health, animal health, and crop protection, serving markets that seek alternatives to traditional drug administration and chemical pesticides. The company's core product involves genetically modified, inactive algae that bio-encapsulate therapeutic proteins, enabling oral delivery and targeted action. TransAlgae operates within the Health Tech & Life Sciences sector, with specific applications in Pharma & Medical Biotechnology, Drug Delivery, Sustainable Farming, and Pest Control.

Strategic signal

In March 2021, TransAlgae announced a collaboration with Virbac to develop an algae-based oral delivery vaccine. This partnership signals a significant validation of TransAlgae's platform by a major animal health pharmaceutical company, indicating potential for accelerated product development and market penetration in the veterinary vaccine space. For investors, this collaboration suggests a strategic move towards commercialization and de-risking of its technology through established industry players.

Company Intelligence Q&A

What is TransAlgae's core technology?

TransAlgae develops an algae-based platform for the oral delivery of drugs such as vaccines, immune modulators, and insecticides. This technology utilizes genetically modified algae to express and deliver therapeutic proteins in a bio-encapsulated form.

What was a key development for TransAlgae in April 2021?

In April 2021, TransAlgae raised an additional $2.5M to advance its algae-based oral vaccine solution, demonstrating continued investment in its innovative drug delivery platform.

How does TransAlgae's technology benefit animal health?

TransAlgae's oral-delivery technology aims to replace the need for antibiotics and vaccination by injections in animal health. Its algal powder, containing the desired drug or vaccine, can be used as a feed supplement for oral vaccination.

What is TransAlgae's approach to crop protection?

TransAlgae has developed a proprietary platform for delivering biological-based insecticides via spraying on crops. This technology enables targeted insect control, reducing the reliance on toxic chemicals.

What is the significance of TransAlgae's partnership with Virbac?

In March 2021, TransAlgae partnered with Virbac to develop an algae-based oral delivery vaccine. This collaboration is a strategic move to advance and commercialize its vaccine technology within the animal health sector.